Synchron Raises $200M Series D to Boost BCI Commercialization and Innovation
Synchron announced a $200 million Series D financing round to accelerate the commercialization of its brain-computer interface (BCI) system, Stentrode. Based in New York, the company will use the funds to advance pivotal trials and develop next-generation interfaces.
Funding and Growth Plans
- The new financing brings Synchron’s total funding to $345 million.
- Synchron plans to expand its team with engineers, neuroscientists, and operators to support its technology development.
- The company is growing its Cognitive AI division in New York to build models that decode thoughts from brain data in real time.
- It has also launched a new engineering hub in San Diego focused on building advanced brain interfaces.
Investor Participation
Double Point Ventures led the round, joined by existing investors ARCH Ventures, Khosla Ventures, Bezos Expeditions, NTI, and METIS. New investors include:
- Australian National Reconstruction Fund (NRF)
- T.Rx Capital
- Qatar Investment Authority (QIA)
- K5 Global
- Protocol Labs
- IQT
About Stentrode BCI
Stentrode — which is implanted through an endovascular approach — detects motor intention from blood vessels within the brain.
Synchron claims its BCI uniquely captures brain signals by accessing blood vessels, placing the implant on the surface of the motor cortex via the jugular vein.
Summary
Synchron’s $200 million funding round propels the commercialization of its unique vascular-implanted BCI and supports ongoing development of next-generation brain interfaces.
Would you like a more technical or user-friendly tone for this text?